Faculté de médecine Faculté de médecine

Deliverables

The Viral Vector Facility can clone, produce and deliver batches of viral vectors, and provide related resources such as plasmids, cells, scientific and technical advice, to research groups at the University of Geneva and HUG.

 

Production of Lentivectors

  • The Viral Vector Facility produces all types of lentivectors for research or pre-clinical application.
  • The standard size of one batch is approximately 10e6 à 10e8 infectious particles, depending on the size and nature of the inserts. Larger batches can be produced upon request.
  • Production includes functional titration using FACS and/or qPCR.
  • The lentivectors can be designed to express proteins or microRNAs, under the control of ubiquitous, tissue-specific, or inducible promoters.
  • Other lentivectors using systems such as CRISPR/Cas9 can also be produced.

Cloning of Lentivectors

  • The Viral Vector Facility can also clone specifically tailored lentivectors upon request.
  • Cloning has been made easier and faster using the Gateway recombination system. This system is incorporated in all our new lentivector backbones, and we have an important repository of genes and promoters already in pENTR plasmids.

Repository of plasmids and cells

  • We have a plasmid bank of 1000+ plasmides, allowing either direct production of already existing lentivector plasmids, or "off-the-shelf" cloning from existing pENTR plasmids (genes, promoters, miRNAs), or rapid PCR cloning of pENTR modules from other plasmids in our repository.
  • We also have a bank of cells dedicated to production and titration of lentivectors.

Other services

  • Thanks to our expertise of more than 20 years in lentivectors, we can provide scientific and technical advice concerning the use of lentivectors. We can also help in the design of experiments using lentivectors either in vitro or in vivo.
  • The Viral Vector Facility can also perform RCL assays (Replication Competent Lentivirus) for biosafety assessment or declassification of transduced cells.
  • The Viral Vector Facility will also develop technologies for the production of Adeno-Associated Vecteurs (AAVs) and other viral vectors upon request.